Biocon Biologics and Viatris Inc. Receive Historic Approval for First Interchangeable Biosimilar Semglee for the Treatment of Diabetes
Interchangeable Designation Allows Substitution at the Pharmacy Counter for Lantus Across the U.S. to Help Increase Access to Medicines for People Living with Diabetes...
Jul 29